Navigation Links
SyntheMed Announces New Management Appointments

ISELIN, N.J., Oct. 2 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD) announced today that Richard L. Franklin, MD, the company's Chairman, has assumed the newly-created position of Executive Chairman and Gere S. diZerega, MD, one of the company's clinical advisors, has assumed the newly-created position of Medical Director. In these consultancy roles, Dr. Franklin will be primarily involved with strategic planning, external communications and Board leadership whereas Dr. diZerega will focus on clinical and regulatory strategy and product planning. Robert P. Hickey, the company's President & CEO stated, "We are very fortunate that Rick and Gere have agreed to expand their involvement with our company and we look forward to benefiting from their experience and expertise."

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products and other surgical implants based on its proprietary bioresorbable polymer technology. The company is developing a portfolio of anti-adhesion products lead by REPEL-CV(R) Adhesion Barrier, an anti-adhesion product intended for use in open heart surgical procedures. REPEL-CV is currently marketed internationally and is awaiting FDA approval to market in the United States.

Statements in this press release that are not statements of historical fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the company, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such risks and uncertainties include but are not limited to (i) potential adverse developments regarding the company's efforts to obtain and maintain required regulatory approvals; (ii) potential inability to secure funding as and when needed to support the company's future activities and (iii) unanticipated delays associated with manufacturing and marketing activities. Reference is made to the Company's Annual Report on Form 10-KSB for the year ended December 31, 2007 for a description of these, as well as other, risks and uncertainties.

SOURCE SyntheMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed Completes $4.0 Million Equity Placement
2. SyntheMed To Present at the AdvaMed 2008 MedTech Conference
3. SyntheMed to Present at Canaccord Adams Small-Cap Orthopedics Conference
4. SyntheMed Files Universal Shelf Registration
5. SyntheMed to Present at the Acumen BioFin Conference
6. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
7. Alba Therapeutics Corporation Announces Promotions
8. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
9. 23andMe Announces Breast Cancer Initiative
10. Exiqon A/S Today Announces a Grant of License to Roche Diagnostics
11. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
Post Your Comments:
(Date:11/26/2015)... CHESHAM , England , November 26, ... Lightpoint Medical, an innovative medical device company specializing in ... Euro grant from the European Commission as part of the ... enabling the company to carry out a large-scale clinical trial ... -->      (Logo: , ...
(Date:11/25/2015)... -- PharmAthene, Inc. (NYSE MKT: PIP) announced  today that its ... (Rights Plan) in an effort to preserve the value ... 382 of the Internal Revenue Code (Code). ... its NOLs could be substantially limited if the Company ... of the Code. In general, an ownership change occurs ...
(Date:11/25/2015)... Studies reveal the differences in species of ... way for more effective treatment for one of the most ... --> --> Gum disease is ... yet relatively little was understood about the bacteria associated with ... by researchers from the WALTHAM Centre for Pet Nutrition together ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/12/2015)... 12, 2015  A golden retriever that stayed healthy ... (DMD) has provided a new lead for treating this ... Broad Institute of MIT and Harvard and the University ... Cell, pinpoints a protective gene ... disease,s effects. The Boston Children,s lab of Lou ...
(Date:11/11/2015)... MedNet Solutions , an innovative SaaS-based eClinical technology company that ... announce that it will be a Sponsor of the ... held November 17-19 in Hamburg , Germany.  ... iMedNet , MedNet,s easy-to-use, proven and affordable eClinical ... able to deliver time and cost savings of up to ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
Breaking Biology News(10 mins):